van Driel M F
Universitair Medisch Centrum Groningen, afd. Urologie, 9700 RB Groningen.
Ned Tijdschr Geneeskd. 2006 Jul 22;150(29):1613-6.
Three different phosphodiesterase 5 (PDE5) inhibitors are currently available for the treatment of erectile dysfunction: sildenafil, vardenafil and tadalafil. The differences between these 3 are limited: tadalafil has a long duration of action, while vardenafil has a rapid onset of action after intake. Various studies have suggested that there is an improvement in the partners' sex lives when men use a PDE5 inhibitor for erectile dysfunction. The introduction of PDE5 inhibitors has renewed the interest in PDE inhibitors in general, for example in the treatment of pulmonary hypertension. In the near future PDE inhibitors may be used for various disorders as chronic obstructive pulmonary disease, benign prostatic hyperplasia, hypertension and coronary heart disease.
目前有三种不同的磷酸二酯酶5（PDE5）抑制剂可用于治疗勃起功能障碍：西地那非、伐地那非和他达拉非。这三种药物之间的差异有限：他达拉非作用持续时间长，而伐地那非服用后起效迅速。各种研究表明，男性使用PDE5抑制剂治疗勃起功能障碍时，其伴侣的性生活会有所改善。PDE5抑制剂的引入总体上重新激发了人们对PDE抑制剂的兴趣，例如在治疗肺动脉高压方面。在不久的将来，PDE抑制剂可能会用于多种疾病，如慢性阻塞性肺疾病、良性前列腺增生、高血压和冠心病。
